Skip to content

Author

Gianpiero Vizzari

We have 2 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

De-escalation of antiplatelet therapy to evaluate platelet reactivity and clinical outcomes after coronary stenting in patients at high bleeding risk and recent acute coronary syndrome: Rationale and design of the DESC-HBR trial.

DesC-HBR is the first randomized trial directly comparing multiple P2Y12 inhibitor de-escalation strategies in HBR patients post-ACS and will provide information to guide individualized antiplatelet strategies balancing ischemic protection and bleeding mitigation in HBR patients.

Francesco Costa, G. Vizzari, S. Zecchino et al. · 0 citations
Open access Jul 2026

Standard clinical and stress electrocardiogram variables to exclude left main and left main-equivalent disease: the MASTER study.

Among CCS patients, LMCAD/LMCAD-equivalent can be excluded with high negative predictive value through a model based on clinical and EST parameters, allowing initial non-invasive management of most patients able to exercise.

M. D. De Carlo, M. A. Malanima, L. Baglietto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.